US8541447B2ExpiredUtilityA1

3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof

76
Assignee: MAZUROV ANATOLY APriority: Feb 21, 2003Filed: Dec 15, 2011Granted: Sep 24, 2013
Est. expiryFeb 21, 2023(expired)· nominal 20-yr term from priority
A61P 9/00A61P 9/10A61P 43/00A61P 37/06A61P 7/02A61P 7/00A61P 25/04A61P 25/34A61P 25/14A61P 35/02A61P 25/30A61P 25/18A61P 25/24A61P 25/16A61P 25/22A61P 35/00A61P 25/02A61P 31/04A61P 29/00A61P 25/32A61P 25/00A61P 25/28A61P 31/12A61P 19/06A61P 17/04A61P 1/02C07D 487/08A61P 11/00A61P 1/04A61P 21/00A61P 19/00A61P 17/06A61P 13/12C07D 453/02C07D 471/08A61P 19/02A61K 51/0455A61P 11/06C07D 453/00
76
PatentIndex Score
1
Cited by
83
References
3
Claims

Abstract

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

Claims

exact text as granted — not AI-modified
That which is claimed is: 
     
       1. A method of ameliorating one or more symptoms associated with Parkinsonism comprising administering to a subject in need thereof a therapeutically effective amount of (R,R;R,S;S,R; and S,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, wherein the administration of (R,R;R,S;S,R; and S,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, improves cognition. 
     
     
       2. A method for treating one or more of Parkinsonism, Parkinson's Disease, cognitive deficits in Parkinson's Disease, and dyskinesias comprising administering to a subject in need thereof a therapeutically effective amount of (R,R;R,S;S,R; and S,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof. 
     
     
       3. A method of providing protective effects against cognitive deficit in Parkinsonism comprising administering to a subject in need thereof a therapeutically effective amount of (R,R;R,S;S,R; and S,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.